ArticlePharmaceuticals (Basel, Switzerland)2019
Radioimmunotherapy in Non-Hodgkin's Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar.
Article in Pharmaceuticals (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 44 citations in OpenAlex.
- Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma.Blood advances · 2020Trial
- Radioligand-Antibody Conjugates: Integrating Antibody Engineering, Chelator Chemistry, and Radioligands for Precision Theranosis.Molecular diagnosis & therapy · 2026Review
- Review
- Affinity- and Format-Dependent Pharmacokinetics ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Optimizing Cancer Treatment: Exploring the Role of AI in Radioimmunotherapy.Diagnostics (Basel, Switzerland) · 2025Review
- Carrier systems of radiopharmaceuticals and the application in cancer therapy.Cell death discovery · 2024Review
- Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells.Frontiers in immunology · 2024Review
- Radiometals in Imaging and Therapy: Highlighting Two Decades of Research.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Cure of Disseminated Human Lymphoma with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma.Expert review of hematology · 2023Review
- Characterization of IGF2R Molecular Expression in Canine Osteosarcoma as Part of a Novel Comparative Oncology Approach.International journal of molecular sciences · 2023Article
- Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors.Clinical and translational science · 2022Article
- The Chemical Scaffold of Theranostic Radiopharmaceuticals: Radionuclide, Bifunctional Chelator, and Pharmacokinetics Modifying Linker.Molecules (Basel, Switzerland) · 2022Review
- Advancing drug safety science by integrating molecular knowledge with post-marketing adverse event reports.CPT: pharmacometrics & systems pharmacology · 2022Review
- A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development.Clinical and translational science · 2022Article
- Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile.Life (Basel, Switzerland) · 2021Review
- Perspectives on metals-based radioimmunotherapy (RIT): moving forward.Theranostics · 2021Review
- Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients.Cancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of monoclonal antibodies has dramatically changed the outcome of patients with non-Hodgkin's lymphoma (NHL), the most common hematological malignancy. However, despite the satisfying results of monoclonal antibody treatment, only few NHL patients are permanently cured with single-agent therapies. In this context, radioimmunotherapy, the administration of radionuclides conjugated to monoclonal antibodies, is aimed to augment the single-agent efficacy of immunotherapy in order to deliver targeted radiation to tumors, particularly CD20+ B-cell lymphomas. Based on evidence from several trials in NHL, the radiolabeled antibodies
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.